Diabetes mellitus is a risk factor for prolonged SARS-CoV-2 viral shedding in lower respiratory tract samples of critically ill patients.


Journal

Endocrine
ISSN: 1559-0100
Titre abrégé: Endocrine
Pays: United States
ID NLM: 9434444

Informations de publication

Date de publication:
12 2020
Historique:
received: 21 06 2020
accepted: 19 08 2020
pubmed: 2 9 2020
medline: 26 11 2020
entrez: 2 9 2020
Statut: ppublish

Résumé

The length of time a critically ill coronavirus disease 2019 (COVID-19) patient remains infectious and should therefore be isolated remains unknown. This prospective study was undertaken in critically ill patients to evaluate the reliability of single negative real-time polymerase chain reaction (RT-PCR) in lower tracheal aspirates (LTA) in predicting a second negative test and to analyze clinical factors potentially influencing the viral shedding. From April 9, 2020 onwards, intubated COVID-19 patients treated in the intensive care unit were systematically evaluated for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by RT-PCR of nasopharyngeal swabs and LTA. The time to negativity was defined as the time between the onset of symptoms and the viral clearance in LTA. In order to identify risk factors for prolonged viral shedding, we used univariate and multivariate Cox proportional hazards models. Forty-eight intubated SARS-CoV-2 patients were enrolled. Overall, we observed that the association of the first negative RT-PCR with a second negative result was 96.7%. Median viral shedding was 25 (IQR: 21.5-28) days since symptoms' onset. In the univariate Cox model analysis, type 2 diabetes mellitus was associated with a prolonged viral RNA shedding (hazard ratio [HR]: 0.41, 95% CI: 0.06-3.11, p = 0.04). In the multivariate Cox model analysis, type 2 diabetes was associated with a prolonged viral RNA shedding (HR: 0.31, 95% CI: 0.11-0.89, p = 0.029). Intubated patients with type 2 diabetes mellitus may have prolonged SARS-CoV-2 shedding. In critically ill COVID-19 patients, one negative LTA should be sufficient to assess and exclude infectivity.

Identifiants

pubmed: 32870469
doi: 10.1007/s12020-020-02465-4
pii: 10.1007/s12020-020-02465-4
pmc: PMC7459254
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

454-460

Commentaires et corrections

Type : CommentIn

Références

Eur Respir J. 2020 Jul 2;56(1):
pubmed: 32398298
Clin Infect Dis. 2020 Nov 19;71(16):2240-2242
pubmed: 32302000
Diabetes Metab Res Rev. 2020 Mar 31;:e3319
pubmed: 32233013
Lancet Infect Dis. 2020 Jun;20(6):656-657
pubmed: 32199493
Nature. 2020 May;581(7809):465-469
pubmed: 32235945
N Engl J Med. 2020 Aug 20;383(8):789-790
pubmed: 32530585
Diabetes Metab Syndr. 2020 Jul - Aug;14(4):513-517
pubmed: 32388331
Am J Med Sci. 2016 Feb;351(2):201-11
pubmed: 26897277
Endocrine. 2020 Apr;68(1):2-5
pubmed: 32279224
Biometrics. 1994 Mar;50(1):61-76
pubmed: 8086616
Clin Infect Dis. 2020 Nov 19;71(16):2249-2251
pubmed: 32306036
Euro Surveill. 2020 Jan;25(3):
pubmed: 31992387
Am J Respir Crit Care Med. 2020 Jun 1;201(11):1435-1438
pubmed: 32293905
Int J Infect Dis. 2020 Jul;96:531-537
pubmed: 32425636
Eur Respir J. 2020 Jul 16;56(1):
pubmed: 32430428
Am J Trop Med Hyg. 2020 Jun;102(6):1210-1213
pubmed: 32342849
BMJ. 2020 Apr 21;369:m1443
pubmed: 32317267
Diabetes Metab Syndr. 2020 Jul - Aug;14(4):303-310
pubmed: 32298981

Auteurs

Niccolò Buetti (N)

Ente Ospedaliero Cantonale, Regional Hospital Locarno, Locarno, Switzerland.
University of Paris, INSERM IAME, U1137, Team DeSCID, Paris, France.
Infection Control Program and World Health Organization Collaborating Centre on Patient Safety, University Hospitals and Faculty of Medicine, University of Geneva, Geneva, Switzerland.

Pierpaolo Trimboli (P)

Faculty of Biomedical Sciences, Università della Svizzera Italiana (USI), Lugano, Switzerland. pierpaolo.trimboli@eoc.ch.
Clinic for Nuclear Medicine and Competence Center for Thyroid Diseases, Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland. pierpaolo.trimboli@eoc.ch.

Timothy Mazzuchelli (T)

Ente Ospedaliero Cantonale, Regional Hospital Locarno, Locarno, Switzerland.

Elia Lo Priore (E)

Ente Ospedaliero Cantonale, Infection Control Program, Ticino, Switzerland.
Ente Ospedaliero Cantonale, Division of Infectious Diseases, Regional Hospital Lugano, Lugano, Switzerland.

Carlo Balmelli (C)

Ente Ospedaliero Cantonale, Infection Control Program, Ticino, Switzerland.
Ente Ospedaliero Cantonale, Division of Infectious Diseases, Regional Hospital Lugano, Lugano, Switzerland.

Alexandra Trkola (A)

Institute of Medical Virology, University of Zurich, Zurich, Switzerland.

Marco Conti (M)

Ente Ospedaliero Cantonale, Regional Hospital Locarno, Locarno, Switzerland.

Gladys Martinetti (G)

Laboratory of Microbiology EOLAB, Bellinzona, Switzerland.

Luigia Elzi (L)

Ente Ospedaliero Cantonale, Regional Hospital Locarno, Locarno, Switzerland.
Division Infectious Diseases, Regional Hospital Bellinzona, Bellinzona, Switzerland.

Alessandro Ceschi (A)

Faculty of Biomedical Sciences, Università della Svizzera Italiana (USI), Lugano, Switzerland.
Division of Clinical Pharmacology and Toxicology, Institute of Pharmacological Sciences of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano, Switzerland.
Department of Clinical Pharmacology and Toxicology, University Hospital Zurich and University of Zurich, Zurich, Switzerland.

Vera Consonni (V)

Ente Ospedaliero Cantonale, Regional Hospital Locarno, Locarno, Switzerland.

Adam Ogna (A)

Ente Ospedaliero Cantonale, Regional Hospital Locarno, Locarno, Switzerland.

Valentina Forni-Ogna (V)

Ente Ospedaliero Cantonale, Regional Hospital Locarno, Locarno, Switzerland.
Faculty of Biomedical Sciences, Università della Svizzera Italiana (USI), Lugano, Switzerland.

Enos Bernasconi (E)

Ente Ospedaliero Cantonale, Division of Infectious Diseases, Regional Hospital Lugano, Lugano, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH